Pharmaceutical Technology, Feb 1, 2013 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Pharmaceutical Technology, Feb 1, 2013
Articles
Building Toolboxes through Cross-Functional Partnerships
By Patricia Van Arnum
When speaking of partnerships, the discussion typically focuses on the relationship between a pharmaceutical/biopharmaceutical company as the sponsor company and a contract-service provider.
The State of Outsourcing Partnerships
By Jim Miller
Preferred-provider relationships are transforming the bio/pharmaceutical industry.
CROs in a Global State of Mind
By Patricia Van Arnum
CROs are keeping pace with the increased globalization of the biopharmaceutical/pharmaceutical industry through a combination of acquisitions, partnerships, and select investments.
Achieving More Effective and Efficient GMP Auditing
By Stefan Kettelhoit , Martin van Trieste
Adherence to GMP in API manufacturing is crucial in determining the safety of drug products.
Survey: Optimizing Global Biopharmaceutical Operations Through Risk Mitigation and Management
By Phil Kaminsky , Jiyang Liu , Julia Olsen-Claire
A UC Berkeley survey provides insight into biopharma's risk concerns and strategies.
The Future of BioPharma
By Eric Langer
Innovation resulting in improved productivity continues unabated and is a primary driver for many of the current biopharmaceutical trends.
Seeking Strength in Partnership Strategies
By Patricia Van Arnum
In the arena of pharmaceutical outsourcing, when speaking of partnerships, the discussion typically focuses on the relationship between a pharmaceutical/biopharmaceutical company as the sponsor company and a contract-service provider.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here